207 filings
Page 4 of 11
8-K
b7mom7ia 8ha753hqd17
10 May 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
65a yfw0zb3stixvwx0
13 Apr 17
IntelGenx and RedHill Biopharma Announce Marketing Approval of RIZAPORT® for Migraines in Luxembourg
12:00am
8-K
geqrge5
5 Apr 17
IntelGenx Files Preliminary Short Form Prospectus In Connection With a Proposed Offering of Convertible Unsecured Debentures
12:00am
8-K
qxco2rp5 ny0rb
3 Apr 17
Other Events
12:00am
8-K
i7ayagr3yy g3
28 Mar 17
Other Events
12:00am
8-K
mhic f9tf
28 Mar 17
Oral Film Exclusivity Granted to IntelGenx’ VersaFilmTM for Tadalafil Erectile Dysfunction Dosing Patent
12:00am
8-K
s7jv42x0isx1
13 Mar 17
Other Events
12:00am
8-K
e19wuedcs6ozj0gx
9 Feb 17
Other Events
12:00am
8-K
ia65el3bi g5qodd
4 Jan 17
IntelGenx Announces Definitive Agreement with Chemo Group for a Generic CNS Tablet
12:00am
8-K
d4tv c7aw3kuy
27 Dec 16
IntelGenx Announces Development and Commercialization Agreement with Endo Ventures
12:00am
8-K
a9xl93w g6v
14 Dec 16
Other Events
12:00am
8-K
e13dvbscv7zv6 pb
1 Dec 16
IntelGenx Strengthens Partnership with Chemo Group by Signing a Co-Development Term Sheet for an Additional Product
12:00am
8-K
rkgot79b2 99o5s
21 Nov 16
IntelGenx Secures a License For Tadalafil Erectile Dysfunction Dosing Patent
12:00am
8-K
0wl8swlmv
10 Nov 16
IntelGenx Reports Profitable Third Quarter with Increased Growth in Revenues from Second Quarter
12:00am
8-K
nfnqn3p
21 Sep 16
Other Events
12:00am
8-K
efutg1h
12 Sep 16
IntelGenx Announces Development and Commercialization Agreement for Three Products with Chemo Group, A Global Pharmaceutical Company
12:00am
8-K
5rs 3j8ai6amm
22 Aug 16
IntelGenx Announces Successful Clinical Study for Montelukastfor the Treatment of Degenerative Diseases of the Brain
12:00am
8-K
xx6nkpa
11 Aug 16
IntelGenx Reports Second Quarter 2016 Financial Results and Appointment of New Director
12:00am
8-K
ogx30f2kc
8 Aug 16
IntelGenx Announces Sale of Forfivo XL®Royalty for $6 Million
12:00am
8-K
39bz8wf
13 Jul 16
Other Events
12:00am